Citation Impact
Citing Papers
Antiproliferative Effects of CDK4/6 Inhibition in CDK4 -Amplified Human Liposarcoma In Vitro and In Vivo
2014
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
2011
Assessment of network perturbation amplitudes by applying high-throughput data to causal biological networks
2012
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Inhibitors of the p53/hdm2 protein–protein interaction—path to the clinic
2013
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Drugging the p53 pathway: understanding the route to clinical efficacy
2014
Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives
2020
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
2020 Standout
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
2017
Clinical Overview of MDM2/X-Targeted Therapies
2016
Cancer-associated cachexia
2018 Standout
Therapeutic strategies to target RAS-mutant cancers
2018
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
2019
Targeting apoptosis in cancer therapy
2020 Standout
Cyclin D as a therapeutic target in cancer
2011
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
2012 StandoutNobel
Targeting RAS–ERK signalling in cancer: promises and challenges
2014
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
2017
MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
2017
The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives
2020 Standout
The use of spirocyclic scaffolds in drug discovery
2014 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
The CDK inhibitors in cancer research and therapy
2011
Prospects for MEK inhibitors for treating cancer
2014
Indoles as therapeutics of interest in medicinal chemistry: Bird's eye view
2017 Standout
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development
2017
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
2018 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA
2018
Advances and controversies in the management of soft tissue sarcomas
2016
Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1α to promote cell-cycle progression
2014 StandoutNobel
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
2013
Precise Modulation of CO2 Sorption in Ti8Ce2–Oxo Clusters: Elucidating Lewis Acidity of the Ce Metal Sites and Structural Flexibility
2024 StandoutNobel
Classification of Intrinsically Disordered Regions and Proteins
2014 Standout
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma
2017
Short Linear Motifs: Ubiquitous and Functionally Diverse Protein Interaction Modules Directing Cell Regulation
2014
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
2013
Causal analysis approaches in Ingenuity Pathway Analysis
2013 Standout
A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)
2019
Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities
2014
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
2017
Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia
2019
Works of Ruediger Rueger being referenced
Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
2012
First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
2012
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
2012
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients
2009
Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.
2011
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
2009